Charles Schwab Investment Management Inc. Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA

Charles Schwab Investment Management Inc. grew its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 4.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 349,023 shares of the company’s stock after purchasing an additional 16,073 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.51% of Olema Pharmaceuticals worth $1,312,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hsbc Holdings PLC acquired a new position in Olema Pharmaceuticals in the fourth quarter valued at about $58,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $64,000. ProShare Advisors LLC lifted its holdings in shares of Olema Pharmaceuticals by 30.2% during the fourth quarter. ProShare Advisors LLC now owns 14,226 shares of the company’s stock worth $83,000 after purchasing an additional 3,298 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Olema Pharmaceuticals by 22.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 14,892 shares of the company’s stock valued at $56,000 after acquiring an additional 2,743 shares during the period. Finally, Polar Asset Management Partners Inc. acquired a new stake in Olema Pharmaceuticals in the fourth quarter valued at $119,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Down 1.1%

Shares of Olema Pharmaceuticals stock opened at $5.46 on Tuesday. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $13.93. The company has a quick ratio of 11.09, a current ratio of 11.09 and a debt-to-equity ratio of 0.01. The stock has a market cap of $374.72 million, a PE ratio of -2.76 and a beta of 1.92. The business has a fifty day simple moving average of $4.96 and a 200 day simple moving average of $4.61.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Research analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on OLMA. Citigroup lifted their price objective on Olema Pharmaceuticals from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, August 12th. The Goldman Sachs Group lowered their price target on Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. JPMorgan Chase & Co. increased their price target on Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Thursday, August 14th. Oppenheimer reduced their target price on Olema Pharmaceuticals from $25.00 to $22.00 and set an “outperform” rating for the company in a report on Wednesday, May 14th. Finally, Zacks Research raised Olema Pharmaceuticals to a “strong sell” rating in a research note on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.